Sooma, a Helsinki-based medical device company, has announced securing €5M in growth funding, led by Voima Ventures, a Nordic early-stage investor. The round also saw participation from Verge HealthTech Fund and existing investor Stephen Industries. This investment will enable Sooma to expand its product development and rapidly extend its reach into new and existing markets globally.
In addition to securing funding, Sooma has recently been awarded an FDA Breakthrough Device Designation. This designation is reserved for novel therapies that demonstrate significant potential to improve treatment options for severe or life-threatening conditions.
Advertisement
Revolutionizing Treatment for Neurological and Psychiatric Disorders
Founded in 2013 by Tuomas Neuvonen, Sooma specializes in non-invasive brain stimulation devices aimed at treating neurological and psychiatric disorders. The company’s portable medical device utilizes Transcranial Direct Current Stimulation (tDCS) to provide a safe, at-home treatment for depression without the need for pharmaceuticals.
tDCS employs a mild electrical current to stimulate the brain, alleviating symptoms of depression without the systemic side effects commonly associated with antidepressant medications. Sooma’s prescription-only therapies can be used as standalone treatments or in combination with other treatment modalities.
Expanding Access to Innovative, Drug-Free Treatment
“Everyone battling depression deserves a chance at a brighter tomorrow. Our innovative, drug-free treatment is designed to be easily accessible from the comfort of your own home. We are dedicated to reaching especially those underserved by medication, or those with limited access to psychotherapy, ensuring everyone suffering from depression has access to the best possible care,” says Tuomas Neuvonen, co-founder and CEO of Sooma.
Sooma’s portable neuromodulation system and digital platform enable clinicians to remotely monitor and customize treatment for multiple patients, improving healthcare efficiency and scalability.
Manufactured to the Highest Standards
Produced in Finland, Sooma’s devices adhere to strict ISO 13485 and MDSAP quality management standards. To date, more than 20,000 patients have found relief with these treatments, according to the company.
Investor Confidence in Sooma’s Vision
Voima Ventures, founded in 2019, focuses on supporting science-based innovations throughout the Nordic and Baltic regions. “Sooma is changing how we tackle depression worldwide. Their at-home brain stimulation therapy offers a powerful way to help people without the need for drugs or the risk of side effects or addiction. I’ve seen firsthand how amazing this technology is across various patient groups, and it’s wonderful to be part of their journey to bring this to more people globally. The battle against depression is only beginning, and it’s time that we start making a change,” says Inka Mero, Founding Partner of Voima Ventures.
With this new funding, Sooma is poised to further its mission of providing effective, accessible treatment solutions for those suffering from neurological and psychiatric disorders, contributing to a brighter future for patients worldwide.
